改善肝硬化患者安全用药的循证建议
该研究基于系统文献检索与10位专家意见,为肝硬化患者制定安全用药建议。共形成218条建议覆盖209种药物,其中31%的药物需调整剂量,约26%的安全性取决于肝硬化严重程度。将建议整合入临床决策支持系统可能提升这一脆弱群体的用药安全。
要点
- 共制定218条建议覆盖209种药物,31%的药物需调整剂量。
- 仅13.3%的建议将药物归类为安全,13.8%为不安全。
- 26.1%的建议中药物安全性取决于Child-Pugh分级。
核心结论
- 为肝硬化患者制定了超过200条安全用药建议,实施这些建议可能改善该脆弱群体的用药安全。
研究设计与样本
- 基于系统文献检索结合10位专家小组的专家意见制定建议,安全性按安全、无额外风险、有额外风险、不安全、未知或取决于Child-Pugh分级分类。
主要发现
- 共制定218条建议,覆盖209种药物;9种药物因给药途径或适应症不同而各有两条建议。
- 29条建议(13.3%)将药物归类为安全,60条(27.5%)为无额外风险,3条(1.4%)为有额外风险,30条(13.8%)为不安全。
- 57条建议(26.1%)中安全性取决于肝硬化严重程度,39条(17.9%)为未知。
- 药效学大幅改变是将药物归类为不安全的主要原因;67种药物(31%)需要调整剂量。
关键数值与推荐
- 安全性分类:安全29条(13.3%)、无额外风险60条(27.5%)、有额外风险3条(1.4%)、不安全30条(13.8%)、取决于肝硬化严重程度57条(26.1%)、未知39条(17.9%)。
- 67种药物(31%)需要剂量调整。
临床怎么用
- 建议已整合入临床决策支持系统和网站,可供处方时参考以提升肝硬化患者用药安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The presence of liver cirrhosis can have a major impact on pharmacodynamics and pharmacokinetics, but guidance for prescribing is lacking. OBJECTIVE: The aim of this study is to provide an overview of evidence-based recommendations developed for the safe use of drugs in liver cirrhosis. METHODS: Recommendations were based on a systematic literature search combined with expert opinion from a panel of 10 experts. The safety of each drug was classified as safe, no additional risks known, additional risks known, unsafe, unknown or the safety class was dependent on the severity of liver cirrhosis (Child-Pugh classification). If applicable, drug-specific dosing advice was provided. All recommendations were implemented in clinical decision support systems and on a website. RESULTS: We formulated 218 recommendations for a total of 209 drugs. For nine drugs, two recommendations were formulated for different administration routes or indications. Drugs were classified as 'safe' in 29 recommendations (13.3%), 'no additional risks known' in 60 (27.5%), 'additional risks known' in 3 (1.4%), and 'unsafe' in 30 (13.8%). In 57 (26.1%) of the recommendations, safety depended on the severity of liver cirrhosis and was 'unknown' in 39 (17.9%) recommendations. Large alterations in pharmacodynamics were the main reason for classifying a drug as 'unsafe'. For 67 drugs (31%), a dose adjustment was needed. CONCLUSIONS: Over 200 recommendations were developed for the safe use of drugs in patients with liver cirrhosis. Implementing these recommendations into clinical practice can possibly enhance medication safety in this vulnerable patient group.
引用
- Weersink RA, Bouma M, Burger DM, et al. Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis. Drug Saf. 2018. PMID: 29330714. doi:10.1007/s40264-017-0635-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。